Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro

Zeruesenay Desta, Tanja Saussele, Bryan Ward, Julia Blievernicht, Lang Li, Kathrin Klein, David A. Flockhart, Ulricht M. Zanger

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Objectives: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the rate of oxidative efavirenz metabolism in human liver microsomes. Materials & methods: Formation rates of 8-hydroxyefavirenz, 7-hydroxyefavirenz and 8,14-dihydroxyefavirenz were determined in vitro with efavirenz as a substrate (10 μM) in a large panel of human liver microsomes (n = 87) that were genotyped for variants of the CYP2B6 gene and phenotyped for CYP2B6 protein expression and bupropion hydroxylation. Results: Efavirenz 8-hydroxylation, the major route of efavirenz clearance, was detected in all samples, exhibiting an overall interindividual variability of 44.7-fold; 8,14-dihydroxyefavirenz and 7-hydroxyefavirenz were also detected in most samples. The formation rate of 8-hydroxyefavirenz correlated significantly with CYP2B6 protein (Spearman's rs = 0.54; p < 0.0001) and bupropion hydroxylase activity (rs = 0.73; p < 0.0001). Compared with the *1/*1 genotype, efavirenz 8-hydroxylation was significantly lower in samples with *1/*6 and *6/ *6 genotype, which also had significantly decreased CYP2B6 protein (Mann-Whitney test, p < 0.05). A decrease in CYP2B6 protein was also observed in samples with *1/*5 and *5/*6 genotypes, but this did not result in significant reduction of efavirenz metabolism, probably due to differences in specific activity of the protein variants. Lower CYP2B6 protein and activity, as well as efavirenz 8-hydroxylation was also found in several samples with rarer genotypes. We found no effect of gender and age on any of the phenotypes tested, but prior exposure to carbamazepine markedly increased CYP2B6 protein expression and activity as well as efavirenz 8-hydroxylation. Conclusions: We have shown that CYP2B6 genetic polymorphism markedly influences the metabolism of efavirenz in human liver microsomes. Importantly, the CYP2B6*6 allele harboring the SNPs c.516G>T [Q172H] and c.785A>G [K262R] was significantly associated with a pronounced decrease in CYP2B6 expression and activity, as well as a low rate of efavirenz 8-hydroxylation. These results represent a first step towards elucidating the mechanism by which this allele identifies patients exhibiting very high efavirenz plasma concentrations.

Original languageEnglish
Pages (from-to)547-558
Number of pages12
JournalPharmacogenomics
Volume8
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

efavirenz
Liver
Hydroxylation
Liver Microsomes
Bupropion
Cytochrome P-450 CYP2B6
In Vitro Techniques
Proteins
Alleles
Genotype

Keywords

  • AIDS
  • Bupropion
  • CYP2B6
  • Cytochrome P450
  • Efavirenz
  • Genetic polymorphism
  • HIV
  • NNRTI
  • Non-nucleoside reverse transcriptase inhibitor
  • Variant allele

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Desta, Z., Saussele, T., Ward, B., Blievernicht, J., Li, L., Klein, K., ... Zanger, U. M. (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics, 8(6), 547-558. https://doi.org/10.2217/14622416.8.6.547

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. / Desta, Zeruesenay; Saussele, Tanja; Ward, Bryan; Blievernicht, Julia; Li, Lang; Klein, Kathrin; Flockhart, David A.; Zanger, Ulricht M.

In: Pharmacogenomics, Vol. 8, No. 6, 06.2007, p. 547-558.

Research output: Contribution to journalArticle

Desta, Z, Saussele, T, Ward, B, Blievernicht, J, Li, L, Klein, K, Flockhart, DA & Zanger, UM 2007, 'Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro', Pharmacogenomics, vol. 8, no. 6, pp. 547-558. https://doi.org/10.2217/14622416.8.6.547
Desta, Zeruesenay ; Saussele, Tanja ; Ward, Bryan ; Blievernicht, Julia ; Li, Lang ; Klein, Kathrin ; Flockhart, David A. ; Zanger, Ulricht M. / Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. In: Pharmacogenomics. 2007 ; Vol. 8, No. 6. pp. 547-558.
@article{2a5e41e3fc074c15900cc728060f41bd,
title = "Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro",
abstract = "Objectives: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the rate of oxidative efavirenz metabolism in human liver microsomes. Materials & methods: Formation rates of 8-hydroxyefavirenz, 7-hydroxyefavirenz and 8,14-dihydroxyefavirenz were determined in vitro with efavirenz as a substrate (10 μM) in a large panel of human liver microsomes (n = 87) that were genotyped for variants of the CYP2B6 gene and phenotyped for CYP2B6 protein expression and bupropion hydroxylation. Results: Efavirenz 8-hydroxylation, the major route of efavirenz clearance, was detected in all samples, exhibiting an overall interindividual variability of 44.7-fold; 8,14-dihydroxyefavirenz and 7-hydroxyefavirenz were also detected in most samples. The formation rate of 8-hydroxyefavirenz correlated significantly with CYP2B6 protein (Spearman's rs = 0.54; p < 0.0001) and bupropion hydroxylase activity (rs = 0.73; p < 0.0001). Compared with the *1/*1 genotype, efavirenz 8-hydroxylation was significantly lower in samples with *1/*6 and *6/ *6 genotype, which also had significantly decreased CYP2B6 protein (Mann-Whitney test, p < 0.05). A decrease in CYP2B6 protein was also observed in samples with *1/*5 and *5/*6 genotypes, but this did not result in significant reduction of efavirenz metabolism, probably due to differences in specific activity of the protein variants. Lower CYP2B6 protein and activity, as well as efavirenz 8-hydroxylation was also found in several samples with rarer genotypes. We found no effect of gender and age on any of the phenotypes tested, but prior exposure to carbamazepine markedly increased CYP2B6 protein expression and activity as well as efavirenz 8-hydroxylation. Conclusions: We have shown that CYP2B6 genetic polymorphism markedly influences the metabolism of efavirenz in human liver microsomes. Importantly, the CYP2B6*6 allele harboring the SNPs c.516G>T [Q172H] and c.785A>G [K262R] was significantly associated with a pronounced decrease in CYP2B6 expression and activity, as well as a low rate of efavirenz 8-hydroxylation. These results represent a first step towards elucidating the mechanism by which this allele identifies patients exhibiting very high efavirenz plasma concentrations.",
keywords = "AIDS, Bupropion, CYP2B6, Cytochrome P450, Efavirenz, Genetic polymorphism, HIV, NNRTI, Non-nucleoside reverse transcriptase inhibitor, Variant allele",
author = "Zeruesenay Desta and Tanja Saussele and Bryan Ward and Julia Blievernicht and Lang Li and Kathrin Klein and Flockhart, {David A.} and Zanger, {Ulricht M.}",
year = "2007",
month = "6",
doi = "10.2217/14622416.8.6.547",
language = "English",
volume = "8",
pages = "547--558",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro

AU - Desta, Zeruesenay

AU - Saussele, Tanja

AU - Ward, Bryan

AU - Blievernicht, Julia

AU - Li, Lang

AU - Klein, Kathrin

AU - Flockhart, David A.

AU - Zanger, Ulricht M.

PY - 2007/6

Y1 - 2007/6

N2 - Objectives: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the rate of oxidative efavirenz metabolism in human liver microsomes. Materials & methods: Formation rates of 8-hydroxyefavirenz, 7-hydroxyefavirenz and 8,14-dihydroxyefavirenz were determined in vitro with efavirenz as a substrate (10 μM) in a large panel of human liver microsomes (n = 87) that were genotyped for variants of the CYP2B6 gene and phenotyped for CYP2B6 protein expression and bupropion hydroxylation. Results: Efavirenz 8-hydroxylation, the major route of efavirenz clearance, was detected in all samples, exhibiting an overall interindividual variability of 44.7-fold; 8,14-dihydroxyefavirenz and 7-hydroxyefavirenz were also detected in most samples. The formation rate of 8-hydroxyefavirenz correlated significantly with CYP2B6 protein (Spearman's rs = 0.54; p < 0.0001) and bupropion hydroxylase activity (rs = 0.73; p < 0.0001). Compared with the *1/*1 genotype, efavirenz 8-hydroxylation was significantly lower in samples with *1/*6 and *6/ *6 genotype, which also had significantly decreased CYP2B6 protein (Mann-Whitney test, p < 0.05). A decrease in CYP2B6 protein was also observed in samples with *1/*5 and *5/*6 genotypes, but this did not result in significant reduction of efavirenz metabolism, probably due to differences in specific activity of the protein variants. Lower CYP2B6 protein and activity, as well as efavirenz 8-hydroxylation was also found in several samples with rarer genotypes. We found no effect of gender and age on any of the phenotypes tested, but prior exposure to carbamazepine markedly increased CYP2B6 protein expression and activity as well as efavirenz 8-hydroxylation. Conclusions: We have shown that CYP2B6 genetic polymorphism markedly influences the metabolism of efavirenz in human liver microsomes. Importantly, the CYP2B6*6 allele harboring the SNPs c.516G>T [Q172H] and c.785A>G [K262R] was significantly associated with a pronounced decrease in CYP2B6 expression and activity, as well as a low rate of efavirenz 8-hydroxylation. These results represent a first step towards elucidating the mechanism by which this allele identifies patients exhibiting very high efavirenz plasma concentrations.

AB - Objectives: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the rate of oxidative efavirenz metabolism in human liver microsomes. Materials & methods: Formation rates of 8-hydroxyefavirenz, 7-hydroxyefavirenz and 8,14-dihydroxyefavirenz were determined in vitro with efavirenz as a substrate (10 μM) in a large panel of human liver microsomes (n = 87) that were genotyped for variants of the CYP2B6 gene and phenotyped for CYP2B6 protein expression and bupropion hydroxylation. Results: Efavirenz 8-hydroxylation, the major route of efavirenz clearance, was detected in all samples, exhibiting an overall interindividual variability of 44.7-fold; 8,14-dihydroxyefavirenz and 7-hydroxyefavirenz were also detected in most samples. The formation rate of 8-hydroxyefavirenz correlated significantly with CYP2B6 protein (Spearman's rs = 0.54; p < 0.0001) and bupropion hydroxylase activity (rs = 0.73; p < 0.0001). Compared with the *1/*1 genotype, efavirenz 8-hydroxylation was significantly lower in samples with *1/*6 and *6/ *6 genotype, which also had significantly decreased CYP2B6 protein (Mann-Whitney test, p < 0.05). A decrease in CYP2B6 protein was also observed in samples with *1/*5 and *5/*6 genotypes, but this did not result in significant reduction of efavirenz metabolism, probably due to differences in specific activity of the protein variants. Lower CYP2B6 protein and activity, as well as efavirenz 8-hydroxylation was also found in several samples with rarer genotypes. We found no effect of gender and age on any of the phenotypes tested, but prior exposure to carbamazepine markedly increased CYP2B6 protein expression and activity as well as efavirenz 8-hydroxylation. Conclusions: We have shown that CYP2B6 genetic polymorphism markedly influences the metabolism of efavirenz in human liver microsomes. Importantly, the CYP2B6*6 allele harboring the SNPs c.516G>T [Q172H] and c.785A>G [K262R] was significantly associated with a pronounced decrease in CYP2B6 expression and activity, as well as a low rate of efavirenz 8-hydroxylation. These results represent a first step towards elucidating the mechanism by which this allele identifies patients exhibiting very high efavirenz plasma concentrations.

KW - AIDS

KW - Bupropion

KW - CYP2B6

KW - Cytochrome P450

KW - Efavirenz

KW - Genetic polymorphism

KW - HIV

KW - NNRTI

KW - Non-nucleoside reverse transcriptase inhibitor

KW - Variant allele

UR - http://www.scopus.com/inward/record.url?scp=34250764311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250764311&partnerID=8YFLogxK

U2 - 10.2217/14622416.8.6.547

DO - 10.2217/14622416.8.6.547

M3 - Article

VL - 8

SP - 547

EP - 558

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 6

ER -